Canada Markets open in 4 hrs 38 mins

T2 Biosystems, Inc. (TTOO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.3889-0.0039 (-0.99%)
At close: 04:00PM EST
0.3817 -0.01 (-1.85%)
After hours: 07:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.3928
Open0.3636
Bid0.3828 x 900
Ask0.3979 x 1100
Day's Range0.3500 - 0.4000
52 Week Range0.3500 - 3.7900
Volume2,830,879
Avg. Volume2,273,762
Market Cap64.545M
Beta (5Y Monthly)0.22
PE Ratio (TTM)N/A
EPS (TTM)-0.3050
Earnings DateMar. 02, 2022 - Mar. 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.78
  • GlobeNewswire

    T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results

    LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021. Recent Highlights (unaudited) Achieved full year 2021 total revenue of $27.7 million, including product revenue of $16.7 million, representing an increase of 53% and 43%, respectively compared to the prior yearAchieved fourth quarter tot

  • GlobeNewswire

    T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial

    LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initation of a U.S. clinical trial evaluating the performance of its T2Biothreat® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA). The T2Biothreat® Panel, which runs on T2 Biosystems’ T2Dx® Instrument, is a direct-from-blood test panel that provides results in 3-5 hours and simultaneously dete

  • GlobeNewswire

    T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial

    LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance® Panel designed to support a submission to the U.S. Food and Drug Administration (FDA). The T2Resistance® Panel, which runs on T2 Biosystems’ T2Dx® Instrument, is a direct-from-blood test panel that detects 13 antibiotic resistance genes